Ontology type: schema:ScholarlyArticle
2017-03-10
AUTHORSHiromasa Katoh, Tsuyoshi Nozue, Ichiro Michishita
ABSTRACTActivated factor-X (FXa) plays an important role not only in the coagulation cascade, but also in pro-inflammatory responses. However, few data exist regarding the anti-inflammatory effect of FXa inhibitors in clinical practice. The aim of this study was to evaluate the anti-inflammatory and anti-atherosclerotic effects of FXa inhibitors in Japanese patients with non-valvular atrial fibrillation (NVAF). Eighty-three patients with NVAF were treated with FXa inhibitors from March 2013 to March 2015 at our institution. Of these, 55 patients who were not pretreated with warfarin or dabigatran (rivarixaban in 23 patients and apixaban in 32) were included in this study. We measured various inflammatory and coagulation markers at baseline and at 6 months after treatment. Plasma concentrations of pentraxin 3 (PTX3) (from 2.45 ± 1.31 to 1.97 ± 1.00 ng/mL, p = 0.0009) and fibrin and fibrinogen degradation products (FDP) D-dimer (from 1.18 ± 0.70 to 0.74 ± 0.32 μg/mL, p < 0.0001) decreased, while those of TM (from 2.9 ± 0.8 to 3.2 ± 0.9 FU/mL, p = 0.003) increased significantly at 6 months. Interestingly, change of each marker denoted the same tendency in both rivaroxaban and apixaban. In conclusion, the present study suggests that FXa inhibitors have not only an anti-coagulant effect but also anti-inflammatory effects in patients with NVAF. Further large-scale prospective study is necessary to evaluate whether changes in these markers will be associated with a lower risk for future cardiovascular events. More... »
PAGES1130-1136
http://scigraph.springernature.com/pub.10.1007/s00380-017-0962-y
DOIhttp://dx.doi.org/10.1007/s00380-017-0962-y
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1084021180
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/28283738
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Cardiorespiratory Medicine and Haematology",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Anticoagulants",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Atrial Fibrillation",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Blood Coagulation",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Factor Xa Inhibitors",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Follow-Up Studies",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Inflammation",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Prospective Studies",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Stroke",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Treatment Outcome",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, 132 Katsura-cho, Sakae-ku, 247-8581, Yokohama, Japan",
"id": "http://www.grid.ac/institutes/grid.417368.f",
"name": [
"Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, 132 Katsura-cho, Sakae-ku, 247-8581, Yokohama, Japan"
],
"type": "Organization"
},
"familyName": "Katoh",
"givenName": "Hiromasa",
"id": "sg:person.01351172112.19",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01351172112.19"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, 132 Katsura-cho, Sakae-ku, 247-8581, Yokohama, Japan",
"id": "http://www.grid.ac/institutes/grid.417368.f",
"name": [
"Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, 132 Katsura-cho, Sakae-ku, 247-8581, Yokohama, Japan"
],
"type": "Organization"
},
"familyName": "Nozue",
"givenName": "Tsuyoshi",
"id": "sg:person.01033145125.12",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033145125.12"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, 132 Katsura-cho, Sakae-ku, 247-8581, Yokohama, Japan",
"id": "http://www.grid.ac/institutes/grid.417368.f",
"name": [
"Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, 132 Katsura-cho, Sakae-ku, 247-8581, Yokohama, Japan"
],
"type": "Organization"
},
"familyName": "Michishita",
"givenName": "Ichiro",
"id": "sg:person.0732262025.70",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732262025.70"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1007/s00380-015-0694-9",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1027777491",
"https://doi.org/10.1007/s00380-015-0694-9"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00380-015-0719-4",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1040134302",
"https://doi.org/10.1007/s00380-015-0719-4"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00380-013-0400-8",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1003231052",
"https://doi.org/10.1007/s00380-013-0400-8"
],
"type": "CreativeWork"
}
],
"datePublished": "2017-03-10",
"datePublishedReg": "2017-03-10",
"description": "Activated factor-X (FXa) plays an important role not only in the coagulation cascade, but also in pro-inflammatory responses. However, few data exist regarding the anti-inflammatory effect of FXa inhibitors in clinical practice. The aim of this study was to evaluate the anti-inflammatory and anti-atherosclerotic effects of FXa inhibitors in Japanese patients with non-valvular atrial fibrillation (NVAF). Eighty-three patients with NVAF were treated with FXa inhibitors from March 2013 to March 2015 at our institution. Of these, 55 patients who were not pretreated with warfarin or dabigatran (rivarixaban in 23 patients and apixaban in 32) were included in this study. We measured various inflammatory and coagulation markers at baseline and at 6 months after treatment. Plasma concentrations of pentraxin 3 (PTX3) (from 2.45\u2009\u00b1\u20091.31 to 1.97\u2009\u00b1\u20091.00\u00a0ng/mL, p\u2009=\u20090.0009) and fibrin and fibrinogen degradation products (FDP) D-dimer (from 1.18\u2009\u00b1\u20090.70 to 0.74\u2009\u00b1\u20090.32\u00a0\u03bcg/mL, p\u2009<\u20090.0001) decreased, while those of TM (from 2.9\u2009\u00b1\u20090.8 to 3.2\u2009\u00b1\u20090.9 FU/mL, p\u2009=\u20090.003) increased significantly at 6 months. Interestingly, change of each marker denoted the same tendency in both rivaroxaban and apixaban. In conclusion, the present study suggests that FXa inhibitors have not only an anti-coagulant effect but also anti-inflammatory effects in patients with NVAF. Further large-scale prospective study is necessary to evaluate whether changes in these markers will be associated with a lower risk for future cardiovascular events.",
"genre": "article",
"id": "sg:pub.10.1007/s00380-017-0962-y",
"inLanguage": "en",
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1095887",
"issn": [
"0910-8327",
"1615-2573"
],
"name": "Heart and Vessels",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "9",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "32"
}
],
"keywords": [
"non-valvular atrial fibrillation",
"anti-inflammatory effects",
"FXa inhibitors",
"atrial fibrillation",
"pentraxin 3",
"Japanese patients",
"large-scale prospective studies",
"future cardiovascular events",
"anti-atherosclerotic effects",
"fibrinogen degradation products D",
"pro-inflammatory response",
"factor Xa inhibitors",
"anti-coagulant effect",
"cardiovascular events",
"coagulation markers",
"prospective study",
"plasma concentrations",
"lower risk",
"clinical practice",
"patients",
"fibrillation",
"inhibitors",
"months",
"markers",
"present study",
"product D",
"dabigatran",
"rivaroxaban",
"apixaban",
"warfarin",
"study",
"baseline",
"important role",
"effect",
"treatment",
"risk",
"fibrin",
"coagulation",
"conclusion",
"same tendency",
"aim",
"changes",
"response",
"factors",
"role",
"events",
"concentration",
"practice",
"institutions",
"data",
"tendency",
"dimer",
"Tm"
],
"name": "Anti-inflammatory effect of factor-Xa inhibitors in Japanese patients with atrial fibrillation",
"pagination": "1130-1136",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1084021180"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s00380-017-0962-y"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"28283738"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s00380-017-0962-y",
"https://app.dimensions.ai/details/publication/pub.1084021180"
],
"sdDataset": "articles",
"sdDatePublished": "2022-06-01T22:16",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220601/entities/gbq_results/article/article_757.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s00380-017-0962-y"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00380-017-0962-y'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00380-017-0962-y'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00380-017-0962-y'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00380-017-0962-y'
This table displays all metadata directly associated to this object as RDF triples.
193 TRIPLES
22 PREDICATES
95 URIs
84 LITERALS
20 BLANK NODES